Product Description
For Treatment of Chronic Hepatitis C (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01740089)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Biocad
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: HIV Infections|Hepatitis C, Chronic|Hepatitis A|Acquired Immunodeficiency Syndrome|Coinfection
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| BCD-016-3 | P3 |
Completed |
Hepatitis C, Chronic|Hepatitis A |
2015-12-02 |
44% |
| BCD-016-4 | P3 |
Completed |
Hepatitis C, Chronic|Acquired Immunodeficiency Syndrome|HIV Infections|Hepatitis A|Coinfection |
2015-08-26 |
|
| PEG-IFNа-2 | P3 |
Completed |
Hepatitis C, Chronic|Hepatitis A |
2012-07-01 |